Beigene Ltd., of Waltham, Mass., part of Beigene Co. Ltd., of Beijing, appointed Amy C. Peterson chief medical officer, immuno-oncology. Peterson will lead the global clinical development of BGB-A317, Beigene’s PD-1 inhibitor; BGB-290, the company’s PARP inhibitor; and the expanding pipeline of other immuno-oncology agents expected to enter clinical development.